Details

Autor(en) / Beteiligte

• Merenstein, D
• Murphy, M
• Fokar, A
• Hernandez, R.K
• Park, H
• Nsouli, H
• Sanders, M.E
• Davis, B.A
• Niborski, V
• Tondu, F
• Shara, N.M

Titel

Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial

Ist Teil von

• European journal of clinical nutrition, 2010-07, Vol.64 (7), p.669-677

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2010

Quelle

MEDLINE

Beschreibungen/Notizen

• Background: To evaluate whether a fermented dairy drink containing the probiotic strain Lactobacillus casei DN-114 001 could reduce the incidence of common infectious diseases (CIDs) and the change of behavior because of illness in children. Subjects/Methods: We conducted a double-blinded, randomized, placebo-controlled allocation concealment clinical trial in the Washington, DC metropolitan area. Participants were 638 children 3–6 years old in daycare/schools. The intervention was a fermented dairy drink containing a specific probiotic strain or matching placebo with no live cultures for 90 consecutive days. Two primary outcomes were assessed: incidence of CIDs and change of behavior because of illness (both assessed by parental report). Results: The rate of change of behavior because of illness was similar among active and control groups. However, the incidence rate for CIDs in the active group (0.0782) is 19% lower than that of the control group (0.0986) (incidence rate ratio=0.81, 95% CI: 0.65, 099) P=0.046. Conclusions: Daily intake of a fermented dairy drink containing the probiotic strain L. casei DN-114 001 showed some promise in reducing overall incidence of illness, but was primarily driven by gastrointestinal infections and there were no differences in change of behavior.